Susquehanna International Group, LLP Neurocrine Biosciences Inc Call Options Transaction History

Susquehanna International Group, LLP

$688 Billion
Q2 2025

Call Options

32 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2025 Aug 14, 2025	BUY	$87.54 - $128.18 $945,432 - $1.38 Million	10,800 Added 10.33%	115,300 $14.5 Million
Q1 2025 May 14, 2025	BUY	$107.22 - $153.29 $1.42 Million - $2.02 Million	13,200 Added 14.46%	104,500 $11.6 Million
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $5.69 Million - $7.11 Million	-51,000 Reduced 35.84%	91,300 $12.5 Million
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $2.57 Million - $3.43 Million	-22,400 Reduced 13.6%	142,300 $16.4 Million
Q2 2024 Aug 15, 2024	SELL	$130.86 - $143.19 $1.99 Million - $2.18 Million	-15,200 Reduced 8.45%	164,700 $22.7 Million
Q1 2024 May 07, 2024	BUY	$130.4 - $143.74 $1.98 Million - $2.18 Million	15,200 Added 9.23%	179,900 $24.8 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $2.24 Million - $2.8 Million	-21,100 Reduced 11.36%	164,700 $21.7 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $3.95 Million - $4.92 Million	42,000 Added 29.21%	185,800 $20.9 Million
Q2 2023 Aug 11, 2023	BUY	$89.53 - $104.87 $8.53 Million - $9.99 Million	95,300 Added 196.49%	143,800 $13.6 Million
Q1 2023 May 16, 2023	BUY	$94.11 - $123.02 $1.21 Million - $1.59 Million	12,900 Added 36.24%	48,500 $4.91 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $3.01 Million - $3.58 Million	-28,200 Reduced 44.2%	35,600 $4.25 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $2.39 Million - $2.8 Million	26,000 Added 68.78%	63,800 $6.78 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $363,792 - $480,335	-4,800 Reduced 11.27%	37,800 $3.69 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $2.02 Million - $2.65 Million	-27,900 Reduced 39.57%	42,600 $3.99 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $477,900 - $637,320	6,000 Added 9.3%	70,500 $6 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $1.59 Million - $1.82 Million	-18,400 Reduced 22.2%	64,500 $6.19 Million
Q2 2021 Aug 11, 2021	SELL	$89.43 - $102.27 $5.63 Million - $6.44 Million	-63,000 Reduced 43.18%	82,900 $8.07 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $4.14 Million - $5.65 Million	47,300 Added 47.97%	145,900 $14.2 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $643,134 - $801,642	-7,400 Reduced 6.98%	98,600 $9.45 Million
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $3.88 Million - $5.46 Million	-40,400 Reduced 27.6%	106,000 $10.2 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $4.78 Million - $7.33 Million	56,200 Added 62.31%	146,400 $17.9 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $7.57 Million - $11.5 Million	-100,800 Reduced 52.77%	90,200 $7.81 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $6.41 Million - $8.75 Million	73,800 Added 62.97%	191,000 $20.5 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $1.07 Million - $1.3 Million	12,800 Added 12.26%	117,200 $10.6 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $549,024 - $693,652	-7,600 Reduced 6.79%	104,400 $8.81 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $18.4 Million - $24.3 Million	-265,100 Reduced 70.3%	112,000 $9.87 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $19.3 Million - $35.2 Million	283,100 Added 301.17%	377,100 $26.9 Million
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $4.13 Million - $5.26 Million	-41,800 Reduced 30.78%	94,000 $11.6 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $10.1 Million - $14.3 Million	-134,700 Reduced 49.8%	135,800 $13.3 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $8.64 Million - $10.5 Million	113,800 Added 72.62%	270,500 $22.4 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $5.43 Million - $7.19 Million	92,700 Added 144.84%	156,700 $12.2 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $3.07 Million - $3.92 Million	64,000	64,000 $3.92 Million

Others Institutions Holding NBIX

# of Institutions

657

Shares Held

101M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account